超声分子成像的研究进展

超声成像无创、无放射性、低成本、实时成像的优点,使其成为目前世界上应用最广的成像手段之一。特别是超声造影剂引入之后,超声成像的图像分辨率和灵敏度得到了大大提高,使超声成像在临床上得到了进一步应用。近年来,随着分子生物学和超声成像技术的不断发展,人们提出了＂超声分子成像＂的概念。它是一项结合了分子靶向造影剂和超声影像技术的能在分子水平下观察病理变化的新兴技术,目前这一技术还处于研究初期阶段。但大量临床前的研究成果已表明超声分子成像在诊断血管生成、炎症和血栓三种疾病具有很大应用前景。本文主要综述了目前常用超声造影剂的种类以及超声分子成像技术的研究现状,并对该技术进行了讨论和展望。     

超声造影在肝脏占位性病变诊断中的应用价值

肝脏是人体最大的腺体.肝脏占位性病变是临床上常见的一类肝脏疾病,这些病变的病理类型复杂,临床上诊断往往十分困难.传统超声在诊断肝脏占位性病变上取得了不小的成绩,但仍有不少局限.超声造影的出现为诊断肝脏占位性病变提供了许多有价值的信息.随着超声造影剂及其成像技术的迅速发展,超声造影技术的临床应用日趋成熟,使肝占位性病变的诊断的准确性及敏感度都有了不小的提高,本文就新型超声造影剂的发展应用在肝占位性病变及肿瘤介入治疗评价中的价值进行综述.     

超声分子成像：机遇与挑战

随着分子生物学、蛋白组学、基因组学、计算机工程学等学科的不断进步,交叉融合,分子成像逐渐登上历史的舞台,成为研究热点。而超声分子成像随之迅猛发展,近年来超声微泡制备技术的成熟和超声造影检查技术的不断进步,超声造影不再局限获取组织的血流灌注信息,而是逐渐成为特异性的超声分子成像。目前使用超声对比剂研究分子成像和靶向治疗仍处于初级阶段。但是,各种分子成像技术的不断革新和发展,超声分子成像面临着重大的挑战,而在挑战背后同样面临着难逢的机遇。超声医学和分子生物学的迅猛发展,超声分子成像必将成为诊断和治疗疾病的新的手段和方法。超声造影剂仍有许多未能解决的问题,像如何延长微泡的半衰期、如何增强微泡的敏感性和特异性,如何增强目的基因的表达,如何处理组织损伤和高频超声之间的关系等问题,但是如果能解决这些问题,超声造影在现代医学的诊断和治疗中将起到重要的作用。现将超声分子成像综述如下。     

多功能磁共振造影剂研究进展

磁共振成像技术因对人体无创、任意方向断层扫描三维图像且分辨率较高、提供形态与功能两方面诊断评价等突出优点,成为了临床上用于疾病诊断的重要手段之一。临床上使用磁共振造影剂可以提高成像的分辨率和灵敏度,提高图像质量,增强对比度和可读性。但是,各种成像技术由于实现原理不同,具有各自的优势和缺陷,靠传统单一的诊断模式无法提供疾病的全面信息,因而在对各种复杂疾病进行诊断时会受到一定的限制。因此,将磁共振成像与其他成像技术如CT成像、超声成像等联合起来使用,则可以达到优势互补的效果,能为疾病的临床诊断提供更快捷精确的信息,同时可将磁共振成像与各种治疗方式结合在一起,即开发基于磁共振成像的诊断治疗一体化试剂,以实现对疾病的即时治疗和实时监控。本文主要介绍了磁共振成像造影剂的原理和种类,并且综述了目前国内外在基于磁共振成像的多功能造影剂/诊疗制剂这一领域的研究进展,最后就未来可能的研究方向进行了展望。     

热声成像技术及其在生物医学中的研究进展

摘要：成像技术在疾病的诊断、治疗和监测中起着重要的作用。热声成像作为一种非电离和非侵入性的新型生物医学成像技术,结合了微波成像高对比度和超声成像高分辨率的优点。因其具有利用内源性对比剂（如水和离子）或多种外源性对比剂（或两者兼有）提供结构、功能、和分子信息的能力,在预临床和临床应用中显示出了巨大的潜力。近几十年来,由于微波辐射源和超声硬件的不断发展,热声成像技术已被广泛用于生物医学成像领域。本文阐述了热声成像的基本原理及成像特点,介绍了近年来热声成像技术在生物医学上的应用、当前在解决相应临床问题应用中的优势及研究现状,最后针对热声成像技术在现有生物医学中面临的挑战对该技术进行了展望。     

光声成像造影剂的研究进展

光声成像(PAT)是利用光声效应获得生物组织或材料的断层图像或三维立体图像的一种成像方法,它兼具光学和声学成像的优点,从而成为目前比较有应用前景的一种成像模式。光声成像造影剂是光声成像的对比增强剂,它通过改变局部组织的声学和光学特性,提高成像对比度和分辨率,从而显著增强光声成像的成像效果,成为当前生物医学领域研究的一个热点。目前常见的光声成像造影剂主要有金纳米材料,碳纳米材料,染料相关纳米材料以及其他纳米材料,这些材料有它们独特的优势,它们尺寸小,稳定性好,具有良好的生物相容性,但在临床应用时本身又存在一些问题。本文综述了光声成像造影剂的种类并简要概述了其研究进展,并对其未来在生物医学领域的应用前景做了进一步展望。     

超声弹性成像技术及其应用

超声弹性成像作为一种新的超声成像方法,它通过获取有关组织弹性信息进行成像,弥补了X射线、超声成像(US)、磁共振成像(MRI)、计算机断层扫描(CT)等传统医学成像模态不能直接提供组织弹性的不足,具有无创、简单、便宜、容易应用等优点,被广泛应用于临床,成为目前医学弹性成像的一个研究热点。本文介绍了弹性成像基本的原理,详细阐述了血管内超声弹性成像、超声振动声成像、超声剪切波弹性成像、瞬时弹性成像、心肌弹性成像等不同激励方式下的几种超声弹性成像的基本原理、成像方法、国内外目前的研究现状、成像优缺点等,叙述了超声弹性成像在乳腺检测、前列腺癌的检测、射频消融监测和检测、冠状动脉粥样硬化的治疗等临床应用,并总结了超声弹性成像的发展趋势。     

超声弹性成像技术在前列腺癌诊断中的应用

超声弹性成像技术是一项新兴的超声成像方法,可通过分析不同组织间机械组织差异区分组织软硬度,早期主要应用于乳腺、甲状腺结节的区分和定性。随着科技的进步和医疗水平的提高,目前弹性成像技术可在二维声像图的基础上,对感兴趣区域进行定性诊断和定量分析,已逐步应用于医学各领域相关研究和临床疾病的鉴别诊断。本文介绍了弹性成像的基本原理和目前弹性成像技术在医学领域中的相关应用,叙述了前列腺癌的发展趋势和目前常用的筛查、诊断方法,详细阐述了弹性成像技术在前列腺癌诊断中的应用方法和现状,分析总结了弹性成像技术在前列腺癌诊断中的应用价值。运用弹性成像技术无创、经济便捷、实时动态、可重复性好等优点,联合前列腺癌相关筛查、诊断检查,可有效帮助早期诊断前列腺癌,减少前列腺穿刺术的针数,提高前列腺癌的检出率。     

磁共振造影剂的研究进展

随着磁共振影像技术的快速发展,MRI在医学领域得到广泛应用,已成为目前临床常规影像诊断方法和手段之一.但MRI对信号探测的敏感性较低,因此需要某些介质在靶组织内大量聚集以达到信号扩增的目的,于是磁共振成像对比剂应用而生.磁共振造影剂(对比剂)可以提高成像分辨率,增加正常与病变组织的成像对比度,从而提高磁共振诊断疾病的敏感性和特异性,目前逐日成为众多学者研究关注的焦点之一.超顺磁性氧化铁纳米粒是一种新型的磁共振对比剂,它的有效成份为纳米级的Fe3O4或Fe2O3晶体核心,主要通过缩短组织中成像水质子的弛豫时间从而加快组织弛豫速率,得以提高正常组织和病灶组织的成像信号对比度,对肝、脾、淋巴结病变的成像效果好,安全性高,能够显著提高小病灶的检出,从而达到早期诊断发现疾病的目的.本文主要就磁共振造影剂的原理、分类及研究进展,尤其是超顺磁性氧化铁在肝脏疾病诊断中的应用进行了综述,并且对磁共振造影剂的未来发展趋势进行了展望.     

生物热应变成像技术的研究进展

热应变成像(thermal strain imaging,TSI)是一种利用超声回波时移的温度相关性进行成像的超声应用.它既具有超声安全、无创和实时成像的优点,又能够显示与其他超声成像方式不同的组织特征,具有良好的应用前景.热应变成像目前在生物医学领域主要应用于组织表征和温度监测两个方面.本综述介绍了热应变成像的基本原理,讨论了适用于临床的主要能量源,并通过回顾近几年热应变成像的研究成果和分析目前面临的局限与挑战,对热应变成像技术的发展进行了探讨和展望.     

Vasa vasorum and molecular imaging of atherosclerotic plaques using nonlinear contrast intravascular ultrasound

There is increasing evidence that presence and location of neovascular vasa vasorum play an important role in atherosclerotic plaque pathogenesis and stability. This paper describes a method to detect vasa vasorum with high contrast and high spatial resolution. It uses second harmonic or subharmonic intravascular ultrasound, in combination with ultrasound contrast agents. The same technology in combination with targeted contrast agents is suited for molecular imaging. The potential for vasa vasorum imaging is illustrated using an atherosclerotic animal model and the potential for molecular imaging is illustrated using phantom experiments.     

Photoacoustic imaging in cancer detection, diagnosis, and treatment guidance

Imaging modalities play an important role in the clinical management of cancer, including screening, diagnosis, treatment planning and therapy monitoring. Owing to increased research efforts during the past two decades, photoacoustic imaging (a non-ionizing, noninvasive technique capable of visualizing optical absorption properties of tissue at reasonable depth, with the spatial resolution of ultrasound) has emerged. Ultrasound-guided photoacoustics is noted for its ability to provide in vivo morphological and functional information about the tumor within the surrounding tissue. With the recent advent of targeted contrast agents, photoacoustics is now also capable of in vivo molecular imaging, thus facilitating further molecular and cellular characterization of cancer. This review examines the role of photoacoustics and photoacoustic-augmented imaging techniques in comprehensive cancer detection, diagnosis and treatment guidance.     

Tailoring the size distribution of ultrasound contrast agents: possible method for improving sensitivity in molecular imaging

Encapsulated microbubble contrast agents incorporating an adhesion ligand in the microbubble shell are used for molecular imaging with ultrasound. Currently available microbubble agents are produced with techniques that result in a large size variance. Detection of these contrast agents depends on properties related to the microbubble diameter such as resonant frequency, and current ultrasound imaging systems have bandwidth limits that reduce their sensitivity to a polydisperse contrast agent population. For ultrasonic molecular imaging, in which only a limited number of targeted contrast agents may be retained at the site of pathology, it is important to optimize the sensitivity of the imaging system to the entire population of contrast agent. This article presents contrast agents with a narrow size distribution that are targeted for molecular imaging applications. The production of a functionalized, lipid-encapsulated, microbubble contrast agent with a monodisperse population is demonstrated, and we evaluate parameters that influence the size distribution and demonstrate initial acoustic testing.     

Molecular imaging with copper-64

Molecular imaging is expected to change the face of drug discovery and development. The ability to link imaging to biology for guiding therapy should improve the rate at which novel imaging technologies, probes, contrast agents, drugs and drug delivery systems can be transferred into clinical practice. Nuclear medicine imaging, in particular, positron emission tomography (PET) allows the detection and monitoring of a variety of biological and pathophysiological processes, at tracer quantities of the radiolabelled target agents, and at doses free from pharmacological effects. In the field of drug discovery and development, the use of radiotracers for radiolabelling target agents has now become one of the essential tools in identifying, screening and development of new target agents. In this regard, (64)Cu (t(1/2)=12.7 h) has been identified as an emerging PET isotope. Its half-life is sufficiently long for radiolabelling a range of target agents and its ease of production and adaptable chemistry make it an excellent radioisotope for use in molecular imaging. This review describes recent advances, in the routes of (64)Cu production, design and application of bi-functional ligands for use in radiolabelling with (64/67)Cu(2+), and their significance and anticipated impact on the field of molecular imaging and drug development.     

Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis

High-frequency microultrasound imaging of tumor progression in mice enables noninvasive anatomic and functional imaging at excellent spatial and temporal resolution, although microultrasonography alone does not offer molecular scale data. In the current study, we investigated the use of microbubble ultrasound contrast agents bearing targeting ligands specific for molecular markers of tumor angiogenesis using high-frequency microultrasound imaging. A xenograft tumor model in the mouse was used to image vascular endothelial growth factor receptor 2 (VEGFR-2) expression with microbubbles conjugated to an anti-VEGFR-2 monoclonal antibody or an isotype control. Microultrasound imaging was accomplished at a center frequency of 40 MHz, which provided lateral and axial resolutions of 40 and 90 Im, respectively. The B-mode (two-dimensional mode) acoustic signal from microbubbles bound to the molecular target was determined by an ultrasound-based destruction-subtraction scheme. Quantification of the adherent microbubble fraction in nine tumor-bearing mice revealed significant retention of VEGFR-2-targeted microbubbles relative to control-targeted microbubbles. These data demonstrate that contrast-enhanced microultrasound imaging is a useful method for assessing molecular expression of tumor angiogenesis in mice at high resolution.